RSS订阅 加入收藏  设为首页
急速赛车是统一开奖么?

急速赛车是统一开奖么?:China Daily reported that the market is in full swing and the midsummer is underway.

时间:2018/5/15 18:45:22  作者:  来源:  浏览:0  评论:0
内容摘要:Continuously growing high-performance stocks over 100 shares Some shares have soared!\u0026nbsp;Recently, the quarterly report of the A-shar...

Continuously growing high-performance stocks over 100 shares Some shares have soared!

\u0026nbsp;Recently, the quarterly report of the A-share listed companies ended, and semi-annual reports were also released one after another. Performance-determined high-growth stocks attracted attention.

GEM in the first quarter to the good performance

A-share listed companies to disclose a quarterly has recently completed a number of companies in the first quarter of 3506 all the "pros and cons" have been presented in front of everyone. By Po chance to statistics, in the first quarter of this year, operating income and net profit growth of respectively 11%, 14%, compared with the same period of the previous year, the growth rate declined. Specifically, nearly 70% year on year in the company's growth in the state; but there are some companies poor performance, performance at a loss.

From the perspective of the sector, the first-quarter performance of ChiNext was encouraging, and the average increase in net profit was nearly 30%, far exceeding the level of the same period in 2017. Shanghai and Shenzhen motherboard and small plates in the first quarter net profit increased by respectively 14%, 18%, lower than the 2017 first quarter. Meanwhile, the A-share performance, a quarter Shenzhen Component Index on the Shanghai Composite Index , , small board index fell across the board, GEM mean market rose 8%, the market has become the only gains across the board in each core sector index .

From the standpoint of the sustainability of performance growth, 130 listed companies made profits in the first three quarters of the last three years, and their net profit increased by more than 30%. Among them, chemical industry, medical biology, and electronics are relatively tight, with each containing more than 10, and these three industries together accounted for 36% of the total.

from the A-share earnings per share reported in the first quarter, the most "profitable" is Moutai , most "dismal" is Nanning Sugar .

as the A-share market price highest price break is also the only first 500 Yuan's company. Kweichow Moutai was not only well-stocked, but its performance was also very bright: In the first quarter of 2018, the company realized operating income of 17.466 billion yuan, an increase of 31.24%; net profit of 8.507 billion yuan, an increase of 38.93%; and earnings per share of 6.77 yuan, was A. The highest earnings per share in a stock company.

From the high of 28.60 yuan in July 2016 to 7.00 yuan today, Nanning Sugar's share price has fallen by over 70% in less than 2 years. Behind this is the deteriorating performance of the company. In the first quarter of 2018, the company achieved operating revenue of 697 million yuan, a year-on-year decrease of 19.95%, and net profit of 194 million yuan, a decrease of 6662.73% from the same period of last year. The basic earnings per share was -0.60 yuan, which was the lowest among all companies in the first quarter.

these shares semi-annual performance growth can be expected

as clear a quarter of the first half performance prediction have been released so far, there are 1094 companies to disclose interim results notice. Among them, pre-growth stocks are 756, annual accounting for nearly 70% 7 _ 89456 _ 44 _ 65473 _ 9.2017 year 2018 first quarter results while high growth (net profit up over 30%) stocks, 110 semi-annual pre-growth and growth range floor more than 30%, these relatively clear performance expectations of the stock of particular concern.

Since the beginning of 2018, the average increase of the aforementioned 110 shares was 4.82%. Among them, 11 stocks rose by 30%, and 784464_49_65473_9 were the top 86.65% gains. When The company reported 2018 first quarter report April 25, 2018, is expected to net profit attributable to shareholders of the magnitude of change in the company's 30% -60% by 2018 half-year, net profit attributable to shareholders of listed companies change interval 3.44 -4.23 billion yuan. The company stated that the reason for the growth in performance was that the company actively expanded the production and sales of vaccines in the first half of the year, and the sales momentum of the products was good. The sales volume continued to grow steadily, resulting in a substantial increase in sales revenue and net profit.

Lepu Medical Since the beginning of the year, the rate of increase was nearly 60%. The company’s semi-annual results announcement for 2018 shows that the net profit attributable to shareholders of listed companies in the first half of the year is expected to increase by 50%-70% compared with the same period of last year; the profit is 743 million yuan – 842 million yuan. The company said that during the reporting period, the company's business continued to grow in the first quarter. In the medical device segment, the stenting business, in vitro diagnostics business and surgical business continued to maintain a relatively fast growth trend. In addition to the rapid growth in the performance of the pharmaceuticals segment, the acquisition of 45% of the minority shareholders of Xindonggang’s shareholdings was consolidated from the second quarter; VAT rate from May 1, 2018 implementation of the adjustment policies, will be the company also expects earnings reporting period have some positive contribution. (Opportunity)

Report Quotes Preview The fund's selection of excellent benchmarks

\u0026nbsp;After completion of the 2017 annual report of the listed company and the disclosure of the quarterly report this year, the company's interim results announcements have gradually revealed. Recently, some particular subject is the subject of blue-chip Daily News quotes progressed, the fund institutional ownership situation is causing concern. For funding agencies, carefully selected blue-chip target to become the best choice under the current structural market environment.

blue chip stocks Daily News quotes expand

statistics show that as of May 14, the two cities, nearly a thousand of listed companies in reporting the results of early warning information release. Among them, the performance is pre-hi (including pre-increase, a slight increase, continued earnings, losses) of listed companies accounted for more than 70%. Specifically, reporting the results pre-hi companies, bio-medicine, chemical raw materials, special equipment higher proportion of companies and other industries.

to small plates, for example, Merchants Securities research report , as of May 4, 2018, small plates mid-year report Announcements / Express disclose the proportion was 99%. Value is calculated according to the disclosure of company performance forecast, the report accumulated earnings growth was 14.9%, Q2 and Q1 single-quarter earnings growth of 8.1% and 24.3%, respectively. Overall pre-hi rate of 72.8%, better profitability of the industry concentrated in electronics, machinery and equipment, bio-pharmaceutical, textile and garment , food and beverage, computers, media, and chemical.

in reporting the results pre-hi companies, a huge part of the growth performance of the company. Take Zhuo Wing Science and Technology as an example, the company quarterly report shows that the net profit attributable to shareholders of the listed company is expected to reach 35-45 million yuan in the first six months of this year, an increase of 1831.89%-2383.85% year-on-year. The company stated that the performance changes the reason the Department of "millet phones and other new customers, continuously introduced new products, performance gradually released, and the equity investment and project implementation capacity expansion and efficiency."

The listed company's mid-year performance has gradually revealed, and the company's market conditions have gradually progressed. In the current market environment, the blue flag will undoubtedly win the favor of the market. According to the statistical data of the data, the top five net listed companies have been sorted by the maximum range of forecast net profit. Since May, the average increase of 7 trading days since May 13 was 6.34%, and the average growth rate of the top ten listed companies has increased. It is 3.06%. In the same period, the Shanghai Composite Index rose 2.63%, the Shenzhen Component Index rose 3.00%, and the ChiNext rose 1.62%. It can be seen that listed companies with great pre-job performance in the secondary market stage performance.

pre-hi underlying fund selection of blue chip target in reporting the results of

, which naturally attracted funding agencies layout. To Shirong Henderson example, the company notice from January to June net profit profitability compared with last year, profit is expected to 400 million -4.5 million. The company's first quarterly data show that the end of the first quarter, the National Social Security Fund, four hundred and seven combinations, basic pension Insurance fund one thousand and five combination, Cathay Pacific Taurus innovation growth mixed, Central Huijin asset management companies, Cathay poly excellent value Flexible Allocation a long letter to quantify the small-cap stock funds etc. listed its top ten tradable shareholders.

analyst weeks of rain Pacific Securities believes that the year on the occasion, it is necessary to configure the industry concentration is rising, the central valuation uplift strong blue chips, but also configure the "New Blue Chip have a competitive advantage in strategic emerging industries . " As for specific industries, we recommend focusing on medicines, health care, military industry, and semiconductors that benefit from advancement of reforms, benefiting from mass consumption under the trend of consumer upgrading and consumer sinking.

In this regard, we believe that the public offering, whether due to valuation uplift or they have a competitive advantage, continued good performance of the stock performance is the most intuitive indicator. The performance of performance has become an indicator of cross-industry and cross-sector investment. “At the moment, it is recommended to focus on three aspects of performance information, including last year’s annual results reflected in the 2017 annual report, performance data reported in the quarterly report, and mid-year performance forecasts. Concerned about the continuous performance of performance, analyze the structural factors of performance, including The main business conditions, non-recurring gains and losses, etc., this bottom-up screening, behind the industry boom, policy factors, market preferences, etc., is currently the risk of controllable, profitable investment strategy." The public offer people Indicated. (China Securities Journal)

pharmaceutical stocks more than mid-year report pre-hi Qicheng agency layout blue chip stocks advance

\u0026 nbsp; this year, the biggest winner in the A-share market is none other than non-pharmaceutical stocks, brisk movements behind the pharmaceutical sector is a beautiful performance of pharmaceutical stocks Support. At present, 78 of the 280 pharmaceutical biotech enterprises have reported mid-term results, of which 58 companies have pre-joyed, accounting for more than 70%.

Medical stocks this year's big winner

Who has been the biggest winner in the A-share market this year? Of course, none of the non-medical stocks belong.

Since the beginning of the year, the theme investment has taken turns and hot sections have been switched at any time. However, after the wave of emotions has receded, only medical stocks have survived. The biomedical sector was repeatedly sought after by funds. From mid-February to May 4th, the biomedical index rose by 18.64%, while the Shanghai Composite Index fell by 1.24% over the same period.

index counter-attack at the same time, a large wave plate in the pharmaceutical sector the main trend upward move out of shape, Plymouth pharmaceutical , Changchun High-tech , Columbine medicine , Chi fly biology, medical Dunlop, Watson Bio , Huahai Pharmaceutical and other stocks are repeatedly hitting record highs. For example Changchun Hi-tech. After the stock reached a base of RMB148.4/share on February 9 this year, the stock price went up unilaterally and reached RMB 189.3/share on March 12th, and then slightly adjusted and continued to “strengthen” on April 25th. Touched 199.5 yuan / share after a bang "stowed upwards", in the May 4 intraday record high, closing the day reported 209.38 yuan / share, the interval has risen 41.09%.

“The continued strengthening of the biomedical sector mainly benefits from both technical and fundamental support.” Industry insiders said that there is still room for growth in the biomedical sector, and investors can choose investment targets from three dimensions. First, innovative drugs are the strategic direction of pharmaceutical investment, pharmaceutical companies focusing on continuous innovation capabilities, such as pharmaceutical companies, growth hormone, and cell immunotherapy, and other innovative drug companies in various segments; second, the pharmaceutical sector has been adjusted for two years, and the marginal recovery of the industry Focusing on the sub-section at the bottom of boom, the third is that with the accelerating consolidation of the pharmaceutical industry, the concentration of the industry continues to increase, and the performance of the leading companies in the fine-molecule industry grows relatively quickly, and they are optimistic about the industry leader in which the performance growth has become more clear. Such as high-quality generic pharmaceutical leader, pharmaceutical retail leader.

Pharmaceutical Business Performance Continues Beautiful

Behind the eye-catching trend of the pharmaceutical sector this year is the support of the pharmaceutical stocks. Overall, the performance of pharmaceutical companies continued in 2017 and continued to improve. According to the data released by the National Development and Reform Commission, the revenue and total profit of China's pharmaceutical industry continued to grow rapidly in 2017, and the main business income recovered to double-digit growth. The effect of the pharmaceutical innovation policy further showed. According to the latest data from the Ministry of Industry and Information Technology, from January to February of this year, the main business income of the pharmaceutical industry increased by 17.6% year-on-year, and profit increased by 35.5% year-on-year.

Among the pharmaceutical sub-sectors, the strongest growth rate of net profit in 2017 was in the manufacture of bio-pharmaceuticals (26.8%) and chemical preparations (22.1%), followed by processing of Chinese herbal decoction pieces (15.1%), manufacture of sanitary materials and medical supplies. (14.4%), chemical raw material drug manufacturing (13.7%).

Up to now, 78 of the 280 pharmaceutical bio-enterprises have reported mid-term results, of which 58 companies have reported fortunes (pre-increase + slightly increase + deficit), accounting for 74%. Among them, net profit expected by more than 50% of companies have 22, including haipurui , Millenia health , Koon Fook , new shares and to , Kingdomway , Cologne medicine , purple Xin Pharmaceutical , wide reputation far , Zhenghai biological , Dunlop medical; net profit expected by more than 30% are Wing Pharmaceutical , SL Pharmaceutical 7_8945 6_219_65473_9, East-Pharmaceutical , Xian Ju Pharmaceutical , biological longevity, sunflower Pharmaceutical 6 company.

Judging from the industries in which the above-mentioned companies with large increase in performance are located, chemical raw material medicine, chemical preparations, Chinese medicines, and biological products are still the most frequent sub-sectors in terms of performance. Take chemical raw material medicine as an example. Since the prices of raw materials such as vitamin A, vitamin C, and amoxicillin have risen sharply, the sector’s revenue and profits have maintained high growth since the first quarter of this year. Taking Hai Purui as the representative, in the first quarter of this year, the company realized a net profit of 41.982 million yuan, turning losses into profits. The company expects its net profit for the first half of this year to reach 110 million to 140 million yuan, a year-on-year increase of 1376.49% to 1779.17%.

Numerous pharmaceutical stocks gain fund holdings

According to the annual report, from the perspective of positions held by public funds, many pharmaceutical stocks have been opened at the end of the fourth quarter of last year, and the proportion of turnover stocks in fund-raising shares has increased. stocks, including open medical , Medicines , Topchoice medical , - Friends of the shares , Changchun High-tech, pharmaceutical and other Plymouth.

The list of the top ten circulation shareholders of Open Healthcare shows that there are 7 public funds and 2 fund accounts, 3 of which are public funds and 2 fund accounts are new shareholders. Buying 2.69 million shares in China-European small and medium-sized board has become The largest circulation shareholder, the proportion of shares outstanding reached 6.73%, China-Europe New Dynamics, Dacheng Internet bought 1.1 million new shares and 550,000 shares respectively, which were the 4th and 10th largest circulation shareholders. Dacheng Value Growth, Guangfa Healthcare, Harvest Medical, and Dacheng Featured all increased their holdings in the fourth quarter of last year. At the end of the third quarter of last year, the number of shares held by the 1st and 10th largest circulating shareholders of Kaili Medical was only 1.84 million shares and 31 million shares respectively. This shows that in the fourth quarter, under the background of institutional holdings increased by , the concentration of chips was further increased.

Sinopharm Co., Ltd. received two social security fund holdings. The National Social Security Fund's 2003 portfolio increased 1.87 million shares in the fourth quarter of last year, holding a total of 13 million shares, making it the second largest circulation shareholder. Newly bought 4.66 million shares. Among the public funds, HSBC's Jinxin dual-core strategy buys 6.75 million shares and is also one of the top ten circulating shareholders. At the end of the third quarter, the one-hundred and four-hundred and fourteen-two stocks holding 3.67 million shares and 3.16 million shares were squeezed out of the top ten shareholders of circulation because of their smaller shareholdings, and could not be judged whether to reduce their holdings. However, no one can, Sinopharm is one of the social security fund's favorite stocks.

General Policy Medical has also been increased by several institutions. Harvest is afraid of long-term gains and Huitianfu Healthcare will increase its shareholding of more than 2.2 million shares in the fourth quarter of last year, while Harvest's lead growth and Harvest's optimization bonus will buy new shares of 4.33 million shares and 3.52 million shares. The social security fund combination also added 1 million shares. (Investment Express)

blue-chip fund

the phone can buy a fund account, click here to download immediately 7_89456_3 49_65473_9
Fund Code fund referred near March earnings fee operating
001071 Hua Internet media mix 26.16 1.50% 0.15% % Purchase Opening Account Purchase
502056 Guangfa Medical Index Grading 23.53% 0.50 % 0.05% purchase account purchase
519698 Bank Pioneer Hybrid 16.95% 1.50 % 0.15% buy Wells Fargo account to purchase
001268 national security themes mixed 12.21% 1.50% 0.15% purchase account to buy
001227 Post information industry Flexible Allocation 11.78% 1.50 % 0.15% purchase account purchase
Source: Oriental Fortune Choice data , Galaxy Securities, as of the date: 2018-05-14



相关评论

本类更新

本类推荐

本类排行

本站所有站内信息仅供娱乐参考,不作任何商业用途,不以营利为目的,专注分享快乐,欢迎收藏本站!
所有信息均来自:百度一下 (玩急速赛车有挣钱的吗_)
蜀ICP备1201564650号